Lacticaseibacillus paracasei strain Shirota (LcS)
Also called: Lactobacillus casei Shirota, Lactobacillus casei strain Shirota, L. casei Shirota, LcS, L. paracasei Shirota YIT 9029
Lacticaseibacillus paracasei strain Shirota YIT 9029 (LcS), formerly called Lactobacillus casei strain Shirota, is a lactic acid bacterium long used in probiotic food products. Most trials gave it in fermented milk drinks. Results here are for this strain.
- Category
- Probiotic
- Forms
- Live bacteria, mostly studied in fermented milk drinks; amounts stated as CFU or viable cells
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-30
Class 1 Well studied in people. No review we found pools 5 or more RCTs of LcS alone. We confirmed 12 randomized trials of LcS versus placebo or no product (2003–2025): constipation and hard stools (two), IBS, antibiotic-associated diarrhea, respiratory infections (three), sleep, cirrhosis, knee osteoarthritis, fracture recovery and NK-cell activity. [6]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Stool frequency and consistency in adults with functional constipation | C | In a 2014 meta-analysis, L. casei Shirota did not significantly change stool frequency (-0.2 bowel movements/week) or stool consistency, unlike B. lactis; attrition and reporting bias were high across trials. [3] |
| Irritable bowel syndrome | C | A 2026 meta-analysis of 2 placebo-controlled RCTs found no significant effect of L. casei Shirota on abdominal pain, bloating, flatulence or overall IBS symptoms. [4] |
| Antibiotic-associated diarrhea in hospitalized patients with spinal cord injury | C | In an RCT of 164 patients (control: no probiotic), daily LcS during antibiotics and for 7 days after was associated with less antibiotic-associated diarrhea (17.1% vs 54.9%); authors called for a placebo-controlled trial. [5] |
| Respiratory symptoms in nursing-home residents aged 65 or older | X | In a double-blind RCT of 737 residents in 53 nursing homes, 176 days of LcS fermented milk had no significant effect on respiratory symptoms or on antibody response to influenza vaccination. [6] |
| Upper respiratory infections in middle-aged office workers | C | In an RCT of 96 male office workers, 12 weeks of LcS fermented milk was associated with fewer upper respiratory tract infections than control milk (22.4% vs 53.2%). [7] |
| Sleep quality under academic examination stress | C | In a double-blind RCT of 94 medical students, LcS fermented milk for 8 weeks before and 3 weeks after an exam improved some subjective sleep scores and maintained deep (N3) sleep versus placebo milk. [8] |
Main constituents: Lacticaseibacillus paracasei strain Shirota YIT 9029 (LcS; formerly Lactobacillus casei strain Shirota YIT 9029) [1]; Cell-wall neutral polysaccharides LCPS-1 and LCPS-2; LCPS-1 is associated with the strain's immunomodulatory functions [1]; Genus Lacticaseibacillus: one of 23 novel genera proposed in the 2020 reclassification of Lactobacillus [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Antibiotic-associated diarrhea trial: a commercial drink with at least 6.5 x 10^9 live LcS once daily during the antibiotic course and for 7 days after. [5]
- Nursing-home trial: 2 bottles/day of fermented milk, each with at least 6.5 x 10^9 live LcS, for 176 days. [6]
- Office-worker trial: fermented milk with 1.0 x 10^11 viable LcS once daily for 12 weeks. [7]
- US hard-stool trial: 80 mL fermented milk with 8.0 x 10^9 CFU LcS/mL daily for 28 days (open-label, no-intervention control). [9]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Antibiotics (timing)
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsStated
Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Lacticaseibacillus paracasei: 1.0 x 10^7 total CFU or more per day …
Details and sources
- In a pilot safety study of 28 critically ill, enterally fed children, LcS was cultured from feces but no colonization or bacteremia with LcS was found in surveillance cultures. [17]
- In an RCT of 92 patients with cirrhosis, LcS three times daily for six months did not change infection rates and was reported safe. [13]
- In the 2026 IBS meta-analysis, adverse-effect rates with L. casei Shirota did not differ significantly from placebo. [4]
- FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [19]
- Health Canada's probiotics monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma or long-term corticosteroid treatment). [20]
Interactions
| With | What happens |
|---|---|
| Antibiotics (timing) | Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Lacticaseibacillus paracasei, at least 2–3 hours before or after antibiotics. [20] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- A study by Yakult Central Institute researchers found that flow cytometry of carboxyfluorescein efflux tracked colony-forming LcS cells in stored fermented milk and proposed it as an alternative to conventional CFU counting. [18]
- Health Canada requires each strain to be identified by phenotype and genotype (including whole-genome strain characterization), absence of virulence to be shown, and at least 80% of the label-declared quantity to remain at the end of shelf life. [20]
- US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [19]
Regulatory status
- Canada: Lacticaseibacillus paracasei (formerly Lactobacillus paracasei) is listed in Health Canada's probiotics monograph (April 24, 2026) for general uses; labels must state the strain designation. [20]
- US: No NDI notification naming the Shirota strain (L. casei or L. paracasei Shirota) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); other L. casei and L. paracasei strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [21]
- US: FDA's GRAS Notice Inventory lists GRN 429 (Lactobacillus casei strain Shirota in fermented dairy products at up to 4 x 10^8 CFU/mL); FDA's letter (closed December 10, 2012): 'FDA has no questions'. [22]
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [23]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming the Shirota strain (L. casei or L. paracasei Shirota) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); other L. casei and L. paracasei strains appear. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
- FDA's GRAS Notice Inventory lists GRN 429 (Lactobacillus casei strain Shirota in fermented dairy products at up to 4 x 10^8 CFU/mL); FDA's letter (closed December 10, 2012): 'FDA has no questions'. [P4]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of Lacticaseibacillus paracasei strain Shirota was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P7]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Antibiotics (timing): Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Lacticaseibacillus paracasei, at least 2–3 hours before or after antibiotics. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P9]
- Strain identity by phenotype and genotype (genome-based comparison to type strains and whole-genome strain characterization) — Required by Health Canada's probiotics monograph for each live microorganism. [P5]
- Viable count (CFU) at end of shelf life — Health Canada requires at least 80% of the label-declared quantity at the end of shelf life. [P5]
- Viability by flow cytometry (carboxyfluorescein efflux) as a possible alternative to CFU counting — Proposed for LcS in milk products because efflux-positive cells correlated with colony-forming cells after long cold storage. [P6]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Lacticaseibacillus paracasei: 1.0 x 10^7 total CFU or more per day (total from all live microorganisms in the product) for its general uses. [P5]
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
- Mizukoshi H, et al. Structural determination of the cell wall polysaccharide LCPS-1 in Lacticaseibacillus paracasei strain Shirota YIT 9029. Carbohydr Res 2022;521:108670 (PMID 36103733), 2022-11. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 429, Lactobacillus casei strain Shirota (date of closure Dec 10, 2012), 2012-12-10. hfpappexternal.fda.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- Kubota H, et al. Detection of glycolytically active Lacticaseibacillus paracasei strain Shirota by flow cytometry targeting the efflux activity of fluorescent dye: a potential tool for quality assessment of probiotic cells in milk products. Appl Environ Microbiol 2023;89(4):e0215622 (PMID 37022200), 2023-04-26. pubmed.ncbi.nlm.nih.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- Mizukoshi H, et al. Structural determination of the cell wall polysaccharide LCPS-1 in Lacticaseibacillus paracasei strain Shirota YIT 9029. Carbohydr Res 2022;521:108670 (PMID 36103733), 2022-11. pubmed.ncbi.nlm.nih.gov
- Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
- Dimidi E, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100(4):1075-84 (PMID 25099542), 2014-10. pubmed.ncbi.nlm.nih.gov
- Maslennikov R, et al. Strain-specific systematic review with meta-analysis of probiotics efficacy in the treatment of irritable bowel syndrome. J Clin Med 2026;15(3):1152 (PMID 41682832; full text PMC12898053), 2026-02-02. pmc.ncbi.nlm.nih.gov
- Wong S, et al. A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Br J Nutr 2014;111(4):672-8 (PMID 24044687), 2014-02. pubmed.ncbi.nlm.nih.gov
- Van Puyenbroeck K, et al. Efficacy of daily intake of Lactobacillus casei Shirota on respiratory symptoms and influenza vaccination immune response: a randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents. Am J Clin Nutr 2012;95(5):1165-71 (PMID 22440853), 2012-05. pubmed.ncbi.nlm.nih.gov
- Shida K, et al. Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers. Eur J Nutr 2017;56(1):45-53 (PMID 26419583), 2017-02. pubmed.ncbi.nlm.nih.gov
- Takada M, et al. Beneficial effects of Lactobacillus casei strain Shirota on academic stress-induced sleep disturbance in healthy adults: a double-blind, randomised, placebo-controlled trial. Benef Microbes 2017;8(2):153-162 (PMID 28443383), 2017-04-26. pubmed.ncbi.nlm.nih.gov
- Cook CM, et al. Effect of daily consumption of a fermented milk containing Lacticaseibacillus paracasei strain Shirota (LcS) on stool consistency in United States adults with hard or lumpy stools: a randomized controlled trial. J Nutr 2025;155(4):1183-1192 (PMID 40024315), 2025-04. pubmed.ncbi.nlm.nih.gov
- Koebnick C, et al. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003;17(11):655-9 (PMID 14631461), 2003-11. pubmed.ncbi.nlm.nih.gov
- Thijssen AY, et al. Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2016;28(1):8-14 (PMID 26469356), 2016-01. pubmed.ncbi.nlm.nih.gov
- Lei M, et al. The effect of probiotic Lactobacillus casei Shirota on knee osteoarthritis: a randomised double-blind, placebo-controlled clinical trial. Benef Microbes 2017;8(5):697-703 (PMID 28726510), 2017-10-13. pubmed.ncbi.nlm.nih.gov
- Macnaughtan J, et al. A double-blind, randomized placebo-controlled trial of probiotic Lactobacillus casei Shirota in stable cirrhotic patients. Nutrients 2020;12(6):1651 (PMID 32498372), 2020-06-02. pubmed.ncbi.nlm.nih.gov
- Gleeson M, Bishop NC, Struszczak L. Effects of Lactobacillus casei Shirota ingestion on common cold infection and herpes virus antibodies in endurance athletes: a placebo-controlled, randomized trial. Eur J Appl Physiol 2016;116(8):1555-63 (PMID 27294502), 2016-08. pubmed.ncbi.nlm.nih.gov
- Zhang C, et al. Oral administration of Lactobacillus casei Shirota improves recovery of hand functions after distal radius fracture among elder patients: a placebo-controlled, double-blind, and randomized trial. J Orthop Surg Res 2019;14(1):257 (PMID 31412879), 2019-08-14. pubmed.ncbi.nlm.nih.gov
- Reale M, et al. Daily intake of Lactobacillus casei Shirota increases natural killer cell activity in smokers. Br J Nutr 2012;108(2):308-14 (PMID 22142891), 2012-07. pubmed.ncbi.nlm.nih.gov
- Srinivasan R, et al. Clinical safety of Lactobacillus casei shirota as a probiotic in critically ill children. J Pediatr Gastroenterol Nutr 2006;42(2):171-3 (PMID 16456410), 2006-02. pubmed.ncbi.nlm.nih.gov
- Kubota H, et al. Detection of glycolytically active Lacticaseibacillus paracasei strain Shirota by flow cytometry targeting the efflux activity of fluorescent dye: a potential tool for quality assessment of probiotic cells in milk products. Appl Environ Microbiol 2023;89(4):e0215622 (PMID 37022200), 2023-04-26. pubmed.ncbi.nlm.nih.gov
- NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
- Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA. GRAS Notice Inventory: GRN No. 429, Lactobacillus casei strain Shirota (date of closure Dec 10, 2012), 2012-12-10. hfpappexternal.fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Limosilactobacillus reuteri DSM 17938 · Probiotics · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.